Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study.
Tadayoni R, Waldstein SM, Boscia F, Gerding H, Gekkieva M, Barnes E, Das Gupta A, Wenzel A, Pearce I; BRIGHTER Study Group. Tadayoni R, et al. Among authors: waldstein sm. Ophthalmology. 2017 Dec;124(12):1778-1787. doi: 10.1016/j.ophtha.2017.06.027. Epub 2017 Aug 12. Ophthalmology. 2017. PMID: 28807635 Free article. Clinical Trial.
Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study.
Larsen M, Waldstein SM, Boscia F, Gerding H, Monés J, Tadayoni R, Priglinger S, Wenzel A, Barnes E, Pilz S, Stubbings W, Pearce I; CRYSTAL Study Group. Larsen M, et al. Among authors: waldstein sm. Ophthalmology. 2016 May;123(5):1101-11. doi: 10.1016/j.ophtha.2016.01.011. Epub 2016 Feb 17. Ophthalmology. 2016. PMID: 26896124 Free article. Clinical Trial.
Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER.
Tadayoni R, Waldstein SM, Boscia F, Gerding H, Pearce I, Priglinger S, Wenzel A, Barnes E, Gekkieva M, Pilz S, Monés J; BRIGHTER study group. Tadayoni R, et al. Among authors: waldstein sm. Ophthalmology. 2016 Jun;123(6):1332-44. doi: 10.1016/j.ophtha.2016.02.030. Epub 2016 Mar 30. Ophthalmology. 2016. PMID: 27039022 Free article. Clinical Trial.
Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study.
Larsen M, Waldstein SM, Priglinger S, Hykin P, Barnes E, Gekkieva M, Das Gupta A, Wenzel A, Monés J; CRYSTAL Study Group. Larsen M, et al. Among authors: waldstein sm. Ophthalmol Retina. 2018 Feb;2(2):134-142. doi: 10.1016/j.oret.2017.05.016. Epub 2017 Sep 9. Ophthalmol Retina. 2018. PMID: 31047340 Free article. Clinical Trial.
Neuroretinal atrophy following resolution of macular oedema in retinal vein occlusion.
Podkowinski D, Philip AM, Vogl WD, Gamper J, Bogunovic H, Gerendas BS, Haj Najeeb B, Waldstein SM, Schmidt-Erfurth U. Podkowinski D, et al. Among authors: waldstein sm. Br J Ophthalmol. 2019 Jan;103(1):36-42. doi: 10.1136/bjophthalmol-2017-311614. Epub 2018 Mar 6. Br J Ophthalmol. 2019. PMID: 29511062 Clinical Trial.
73 results